GILD vs VRTX
GILD and VRTX side by side — valuation & fundamentals (public data).
Key statistics
| Metric | GILDGILEAD SCIENCES, INC. | VRTXVERTEX PHARMACEUTICALS INC / MA |
|---|---|---|
| Market cap | $166.66B | $123.24B |
| P/E (TTM) | 18.3 | 28.8 |
| P/B | 7.09 | 6.37 |
| P/S | 5.7x | 10.3x |
| Revenue | $29.74B(TTM) | $12.22B(TTM) |
| Revenue growth (YoY) | 2.4% | 8.9% |
| Net income | $9.22B(TTM) | $4.34B(TTM) |
| Earnings growth (YoY) | 1672.9% | 838.1% |
| EPS, diluted | $7.35(TTM) | $16.85(TTM) |
| EBIT margin | 34.0% | 34.8% |
| ROE | 36.2% | 20.4% |
| ROIC | 21.6% | 25.4% |
| 1y total return | +26.4% | +4.8% |
Figures from SEC filings · for reference only · not investment advice
Crecimiento de $10,000: GILD frente a VRTX
| Métrica | GILD | VRTX |
|---|---|---|
| Valor final | $21.5K | $58.6K |
| Retorno total | +115.1% | +486.3% |
| CAGR | +7.7% | +18.7% |
| Volatilidad | 25.7% | 33.2% |
| Sharpe | 0.27 | 0.57 |
| Sortino | 0.39 | 0.83 |
| Caída máxima | -36.0% | -41.6% |
Basado en 2600 días de negociación comunes, 2016-03-15 → 2026-07-17 · tasa libre de riesgo 3.85% (bono corto del Tesoro actual, mantenido constante)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)